Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen

Welkom bij Scalda & Bohn Stafleu van Loghum

Scalda heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen.Je kunt de producten hieronder links aanschaffen en rechts inloggen.

» Andere revante producten voor Scalda studenten en medewerkers.

Registreer

Schaf de BSL Academy aan: 

BSL Academy mbo AG

Eenmaal aangeschaft kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

Heb je een vraag, neem dan contact op met Jan van der Velden.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Quality of Life Research
Gepubliceerd in:

01-06-2014

Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach

Auteurs: Adin-Cristian Andrei, Kathleen L. Grady

Gepubliceerd in: Quality of Life Research | Uitgave 5/2014

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Background

Vesnarinone Trial (VesT) was a three-armed, placebo-controlled, randomized clinical trial designed to study the effects of 30 mg or 60 mg/day vesnarinone. Certain contradictory results involving patient health-related quality-of-life (HRQOL) and overall survival (OS) have made a definitive and unified conclusion difficult.

Methods

To reconcile these findings, we have focused on the HRQOL-adjusted OS, commonly known as quality-adjusted life years (QALYs). Currently, analyses of QALYs incorporate a single HRQOL subscale. However, the VesT HRQOL instrument had two subscales: physical (PHYS) and emotional (EMOT). We have developed new ways to visualize and compare EMOT- and PHYS-adjusted OS.

Results

In each VesT arm, there was an increased probability of superior EMOT-adjusted OS, compared to PHYS-adjusted OS. The magnitude of these findings was comparable across trial arms. Despite inferior survival and superior EMOT and PHYS scores, the 60-mg/day arm presents similar EMOT- and PHYS-adjusted OS compared to the placebo arm.

Conclusions

We have provided a fresh perspective on the complex interactions between multiple HRQOL dimensions and OS. These novel methods address the burgeoning need for robust information on the interplay between OS and HRQOL from a patient, clinical care and public policy perspective.
volgende artikel Testing gender invariance of the Hospital Anxiety and Depression Scale using the classical approach and Bayesian approach
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
Spilker, B. (1996). Quality of life and pharmacoeconomics in clinical trials (2nd ed.). New York: Lippincott Williams & Williams.
2.
Ware, J. E., Kosinski, M., Dewey, J. E., & Gandek, B. (2000) . SF-36 health survey: Manual and interpretation guide. Quality Metric Inc. Boston: Health Institute, New England Medical Center, 1993.
3.
Parasuraman, S., Hudes, G., Levy, D., Strahs, A., Moore, L., DeMarinis, R., et al. (2007). Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 25(18S), 5049.
4.
Kaarlola, A., Tallgren, M., & Pettil, V. (2006). Long-term survival, quality of life, and quality-adjusted life-years among critically ill elderly patients. Critical Care Medicine, 34(8), 2120–2126.PubMedCrossRef
5.
Muennig, P. A., & Gold, M. R. (2001). Using the years-of-healthy-life measure to calculate QALYs. American Journal of Preventive Medicine, 20(1), 35–39.PubMedCrossRef
6.
Sindelar, J. L., & Jofre-Bonet, M. (2004). Creating an aggregate outcome index: Cost-effectiveness analysis of substance abuse treatment. The Journal of Behavioral Health Services and Research, 31(3), 229–241.PubMedCrossRef
7.
Cohn, J. N., Goldstein, S. O., Greenberg, B. H., Lorell, B. H., Bourge, R. C., Jaski, B. E., et al. (1998). A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. The New England Journal of Medicine, 339, 1810–1816.PubMedCrossRef
8.
Rector, T. S., Kubo, S. H., & Cohn, J. H. (1993). Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. American Journal of Cardiology, 71, 1106–1107.PubMedCrossRef
9.
Torrance, G., & Feeny, D. (1989). Utilities and quality-adjusted life years. International Journal of Technology Assessment, 5, 559–575.CrossRef
10.
Glasziou, P. P., Cole, B. F., Gelber, R. D., Hilden, J., & Simes, R. J. (1998). Quality adjusted survival analysis with repeated quality of life measures. Statistics in Medicine, 17, 1215–1229.PubMedCrossRef
11.
Goldhirsch, A., Gelber, R., Simes, R., Glasziou, P., & Coates, A. (1989). Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. Journal of Clinical Oncology, 7, 36–44.PubMed
12.
Glasziou, P. P., Simes, R. J., Gelber, & R. D. (1990). Quality adjusted survival analysis. Statistics in Medicine, 9, 1259–1276.PubMedCrossRef
13.
Gelber, R. D., Cole, B. F., Gelber, S., & Goldhirsch, A. (1995). Comparing treatments using quality-adjusted survival: The Q-TWiST method. American Statistician, 49, 161–169.
14.
Ahlstrom, A., Tallgren, M., Peltonen, S., Rasanen, P., & Pettila, V. (2005). Survival and quality of life of patients requiring acute renal replacement therapy. Intensive Care Medicine, 31(9), 1222–1228.PubMedCrossRef
15.
Perkins, M., Howard, V., Wadley, V. G., Crowe, M., Safford, M. M., Haley, W. E., et al. (2013). Caregiving strain and all-cause mortality: evidence from the REGARDS study. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 68(4), 504–512.CrossRef
16.
Nichol, M. B., Sengupta, N., & Globe, D. R. (2001). Evaluating quality-adjusted life years estimation of the Health Utility Index (HUI2) from the SF-36. Medical Decision Making, 21(2), 105–112.PubMedCrossRef
17.
Kamel, H., Johnston, S. C., Easton, J. D., & Kim, A. S. (2012). Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke, 43(3), 881–883.PubMedCrossRef
18.
Rogers, J. G., Bostic, R. R., Tong, K. B., Adamson, R., Russo, M., & Slaughter, M. S. (2012). Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circulation: Heart Failure, 5(1), 10–16.
19.
Saarni, S., Suvisaari, J., Sintonen, H., Koskinen, S., Harkanen, T., & Lonngvist, J. (2007). The health-related quality of life impact of chronic conditions varied with age in general population. Journal of Clinical Epidemiology, 60(12), 1288–1297.PubMedCrossRef
20.
Ferguson, N. D., Scales, D. C., & Pinto, R., et al. (2013). Integrating mortality and morbidity outcomes: using quality-adjusted life years in critical trials. American Journal of Respiratory and Critical Care Medicine, 187(3), 256–261.PubMedCrossRef
21.
Lin, D. Y., Sun, W., & Ying, Z. (1999). Nonparametric estimation of the gap time distributions for serial events with censored data. Biometrika, 86, 59–70.CrossRef
22.
Zhao, H., & Tsiatis, A. A. (1997). A consistent estimator for the distribution of quality adjusted survival time. Biometrika, 84, 339–348.CrossRef
23.
Gill, R. D. (1983). Large sample behaviour of the product-limit estimator on the whole line. Annals of Statistics, 11, 49–58.CrossRef
24.
Andrei, A. -C., & Murray, S. (2006). Estimating the quality-of-life-adjusted gap time distribution of successive events subject to censoring. Biometrika, 93(2), 343–355.CrossRef
Metagegevens
Titel
Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach
Auteurs
Adin-Cristian Andrei
Kathleen L. Grady
Publicatiedatum
01-06-2014
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 5/2014
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-013-0608-1

Andere artikelen Uitgave 5/2014

Factors associated with health-related quality of life among pulmonary tuberculosis patients in Manila, the Philippines

Impact of hypoalphalipoproteinemia on quality of life in Taiwanese women with central obesity

The association of PTSD with physical and mental health functioning and disability (VA Cooperative Study #569: the course and consequences of posttraumatic stress disorder in Vietnam-era Veteran twins)

Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: evaluation of the fatigue severity scale

Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer

  • Open Access

Quality of life and related factors: a questionnaire survey of older people living alone in Mainland China